ASCO

Cabozantinib With Nivolumab Extended PFS in Patients With Advanced Recurring Endometrial Cancer

June 08, 2020

ByGabrielle Ientile, Assistant Editor

The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.

ASCO20: Switching to Generic Bortezomib Can Yield Significant Cost Savings

June 03, 2020

ByGabrielle Ientile, Assistant Editor

The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.

Systematic Review Evaluates Cannabis, Cannabinoids in Palliative and Supportive Oncology Care

May 30, 2020

ByJennifer Barrett

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results. 

Adjuvant Osimertinib Therapy Delays Disease Recurrence in Localized NSCLC

May 30, 2020

ByJennifer Barrett

Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.

ASCO20 Virtual: Pembrolizumab Doubles Progression-Free Survival for Certain Advanced Colorectal Cancer Types

May 29, 2020

ByGabrielle Ientile, Assistant Editor

The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.

Study: Inclusion of Oncology Pharmacist Led to Financial, Clinical Benefits in Clinic

May 29, 2020

ByJennifer Barrett

An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.

Latest Global Analysis Examines Mortality Rates of Patients With COVID-19, Thoracic Cancers

May 29, 2020

ByGabrielle Ientile, Assistant Editor

“Data collection is ongoing with additional analyses planned to look at patient and provider perception of COVID-19 impact on cancer care.”

SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer

May 29, 2020

ByGabrielle Ientile, Assistant Editor

SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.

Nationwide Study Shows Cancer Mortality Benefit Following State Medicaid Expansion

May 29, 2020

ByGabrielle Ientile, Assistant Editor

The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.

ASCO20 Virtual: Study Assesses COVID-19 Clinical Data, Finds Cancer Mortality Links

May 28, 2020

ByGabrielle Ientile, Assistant Editor

The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.